Clerodendranthus spicatus inhibits epithelial-mesenchymal transition of renal tubular cells through the NF-κB/Snail signalling pathway in hyperuricaemia nephropathy

Pharm Biol. 2023 Dec;61(1):1274-1285. doi: 10.1080/13880209.2023.2243086.

Abstract

Context: Clerodendranthus spicatus Thunb. (Labiatae) (CS), a perennial traditional Chinese medicinal herb that can reduce serum uric acid (sUA) levels and ameliorate renal function is widely used to treat hyperuricaemic nephropathy (HN).

Objective: To investigate the molecular mechanism of action of CS in HN treatment using in vivo and in vitro experiments.

Materials and methods: Sprague-Dawley rats were randomly divided into control, HN, CS and positive control allopurinol groups. The HN group was intraperitoneally injected with 750 mg/kg oxonic acid potassium (OA), whereas the CS group was injected with OA along with a gavage of CS (low dose 3.125 g/kg, high dose 6.25 g/kg) for five weeks. For in vitro studies, uric acid-treated HK2 cells were used to verify the therapeutic mechanism of CS in HN.

Results: HN rats exhibit pathological phenotypes of elevated sUA levels and renal injury. CS significantly improved these symptoms and sUA (p < 0.05) and blood urea nitrogen (p < 0.01) levels, and dramatically improved renal tubular injury in HN rats. The IC50 value of UA (uric acid) in HK2 cells was 826.32 ± 3.55 μg/mL; however, 120 ng/mL CS had no significant cytotoxicity on HK2 cells. In vivo and in vitro studies showed that CS inhibited NF-κB phosphorylation and inhibited α-smooth muscle actin (α-SMA) and vimentin expression while increasing E-cadherin expression, suggesting that CS inhibited the fibrotic process in renal cells, thus protecting renal function.

Discussion and conclusions: These findings provide a fundamental understanding of the application of CS in HN treatment to better guide clinical interventions.

Keywords: Hyperuricaemic HK2; lowering uric acid; renal protection; traditional Chinese medicine.

MeSH terms

  • Animals
  • Epithelial-Mesenchymal Transition
  • Hyperuricemia* / drug therapy
  • Kidney / physiology
  • NF-kappa B*
  • Rats
  • Rats, Sprague-Dawley
  • Uric Acid

Substances

  • NF-kappa B
  • Uric Acid

Grants and funding

This study was supported by the National Natural Science Foundation of China under Grant [Nos. 82074376 and 81774216]; the Specific Fund of State Key Laboratory of Dampness Syndrome of Chinese Medicine under Grant [No. SZ2020ZZ04, SZ2020ZZ05, SZ2021KF15, SZ2021ZZ1004, SZ2021ZZ50 and YN2016XP01]; the Joint Innovation Project of National Center for Protein Sciences (Beijing) and Guangdong Provincial Hospital of Chinese Medicine under Grant [No. 2017KT1821]; Department of Science and Technology of Guangdong Province [No. 2020A1515110450]; Health Commission of Guangdong Province [No. B2023141]; Traditional Chinese Medicine Bureau of Guangdong Province of China [Nos. 20211183 and 20225009]; the Guangdong Provincial Science and Technology Project under Grant [No. 2018B030322012 and 2022A1515012051]; and the Open Project of State Key Laboratory of Quality Research in Chinese Medicine [MUST-SKL-2016-10] funded by the Macao Science and Technology Development Fund, Macau Special Administrative Region.